Cantor Fitzgerald Reiterates Overweight Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They currently have a $28.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 339.56% from the stock’s current price.

QURE has been the subject of a number of other research reports. StockNews.com raised uniQure to a “sell” rating in a report on Thursday, October 17th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, August 20th. Raymond James reiterated an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a research note on Thursday, October 10th. Finally, The Goldman Sachs Group increased their price objective on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, uniQure presently has a consensus rating of “Hold” and a consensus target price of $19.50.

uniQure Stock Performance

Shares of QURE traded up $0.31 during mid-day trading on Wednesday, reaching $6.37. The company had a trading volume of 22,540 shares, compared to its average volume of 1,405,800. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $310.21 million, a P/E ratio of -1.07 and a beta of 0.90. The stock has a 50 day moving average of $5.68 and a two-hundred day moving average of $5.78.

Institutional Trading of uniQure

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after buying an additional 109,740 shares in the last quarter. Acadian Asset Management LLC raised its stake in uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in uniQure by 74.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock valued at $818,000 after buying an additional 66,958 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in uniQure by 49.1% in the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 89,400 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after purchasing an additional 30,054 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.